Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study.
Jishnu MalgieMariëlle I WildePascal R D ClephasMireille E EmansStefan KoudstaalJeroen SchaapArend MosterdJan van RamshorstAlexander J WardehSandra van WijkMieke van den HeuvelEric WierdaC Jan Willem BorleffsColette SaraberSaskia L M A BeeresRoland van KimmenadeWouter Jansen KlompRobert DenhamCarlos A da FonsecaIJsbrand T KlipOlivier C ManintveldRobert M A van der BoonClara E E van OfwegenAyten YilmazRon PistersGerard C M LinssenNikola FaberLoek van HeerebeekJulio E C van de SwaluwLex J BouhuijzenMarco C PostAaf F M KuijperKa Wai WuEugène A van BeekTim HesselinkLennaert KleijnMaurice J M KurversRené A TioJorina LangerveldBas M van DalenJ W Martijn van EckM Louis HandokoWalter R M HermansHetty J J Koornstra-WortelMariusz K SzymanskiDennis RookerKenneth TandjungSabine C M EijsboutsFolkert W AsselbergsPeter van der MeerHans-Peter Brunner-La RoccaRudolf A de BoerJasper J BrugtsPublished in: European journal of heart failure (2024)
This first analysis of the TITRATE-HF study reports relatively high use of GDMT in a contemporary HF cohort, while still showing room for improvement regarding quadruple therapy. Importantly, the use and dose of GDMT were suboptimal, with the reasons often remaining unclear. This underscores the urgency for further optimization of GDMT and implementation strategies within HF management.